AbbVie Bull Case
Here are some ways that investors could benefit from investing in AbbVie Inc.:
- AbbVie Inc. recently announced positive topline results from the Phase 3 CERVINO trial, where its investigational BCMA x CD3 therapy, etentamig, met both primary endpoints for relapsed/refractory multiple myeloma. The therapy produced a 74% objective response rate compared to 45.7% for standard therapies and reduced the risk of disease progression or death by 60%, which could support a regulatory submission and allow the company to compete in the growing BCMA-targeted treatment market.
- The company completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs to its pipeline. This strategic move strengthens AbbVie Inc.'s growth potential beyond its flagship Humira product and expands its immunology portfolio.
- AbbVie Inc. reported strong second-quarter earnings, with earnings per share of $3.65 beating analysts' consensus estimates of $3.61 by $0.04. Revenue reached $16.99 billion, exceeding the $16.80 billion estimate, and revenue grew 10.2% on a year-over-year basis, demonstrating robust commercial performance and effective execution.
- Key growth products Skyrizi and Rinvoq continue to drive significant sales, with reported second-quarter sales growth of 24% and 25% respectively. These products are effectively offsetting the erosion of Humira revenue, providing a stable foundation for the company's financial health and supporting its long-term investment case.
- AbbVie Inc. maintains a consistent dividend record, having recently declared a quarterly dividend of $1.73 per share, which represents an annualized dividend of $6.92 and a dividend yield of 2.7%. This steady income stream is attractive to investors seeking reliable returns, supported by the company's established financial position.